Evidence map›Paper›PMID 33093945›Full record

ReviewF1000Research2020

Electrolyte Disturbances in SARS-CoV-2 Infection.

Holly Mabillard, John A Sayer

Abstract readReview
In one paragraph

Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. SARS-CoV-2 N protein induces hypokalemia in acute kidney injury mice via ENaC-dependent mechanism.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Article
  4. Review
  5. Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.International journal of medical sciences · 2025
    Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Seizure after recovery from Covid-19.Journal of family medicine and primary care · 2021
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Holly MabillardRenal Services, The Newcastle Hospitals NHS Foundation Trust, Newacstle upon Tyne, Tyne and Wear, NE77DN, UK.
John A SayerRenal Services, The Newcastle Hospitals NHS Foundation Trust, Newacstle upon Tyne, Tyne and Wear, NE77DN, UK.ORCID 0000-0003-1881-3782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global pandemic secondary to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is leading to unprecedented global morbidity and mortality. With a bewildering array of complications, renal involvement in various forms is common, including serum electrolyte derangements. Hypokalaemia secondary to SARS-CoV-2 was common in a reported Chinese cohort. Here we review the emerging evidence on hypokalaemia and SARS-CoV-2 infection, the potential pathophysiological mechanisms based on early clinical and histopathological data and important clinical implications. Mechanisms of hypokalaemia are multifactorial and so the electrolyte disturbance can be difficult to avoid. We provide further support to the theory of renin-angiotensin-aldosterone (RAS) activation, discuss the strengths and weaknesses of implicating RAS involvement and highlight the importance of calculating the transtubular potassium gradient to identify those at risk of hypokalaemia and its complications.

Indexed as

Coronavirus InfectionsHypokalemiaPneumonia, ViralAldosteroneBetacoronavirusCOVID-19ElectrolytesHumansPandemicsPotassiumRenin-Angiotensin SystemSARS-CoV-2AldosteroneElectrolytesPotassiumACE-2alkalosisHypokalaemiaSARS-CoV-2transtubular potassium gradient

Identifiers

PMID33093945
PMCPMC7533733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.